Adversarial Injection · Sotorasib (Lumakras; AMG 510; CAS 2296729-00-3; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-[4-methyl-2-(propan-2-yl)pyridin-3-yl]-4-[(2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl]pyrido[2,3-d]pyrimidin-2(1H)-one; MW ~560.5 g/mol; C29H25F2N5O3; pyrido[2,3-d]pyrimidine scaffold with covalent acrylamide piperazine warhead [THIRTY-SECOND MECHANISM CLASS in Glyphward 567-attack portfolio: KRAS G12C COVALENT ALLOSTERIC INHIBITOR — FIRST KRAS INHIBITOR IN PHARMACEUTICAL HISTORY; KRAS (Kirsten Rat Sarcoma viral proto-oncogene; GTPase; chromosome 12p12.1; MW 21.6 kDa; RAS family) = identified as oncogene 1982 (Kirsten sarcoma virus); mutated in ~25% of all human cancers (G12D ~37%, G12V ~25%, G12C ~13%, G12R ~9%; KRAS = most commonly mutated oncogene in human cancer); KRAS GTPase cycles: GDP-bound inactive → SOS1-catalyzed GTP loading → GTP-bound active → RAF/PI3K/RalGDS effector binding → RAS-RAF-MEK-ERK and PI3K-AKT-mTOR signaling → G12 mutation disrupts GAP (GTPase-activating protein) catalysis of GTP hydrolysis → KRAS locked in GTP-active state → constitutive RAS signaling regardless of upstream RTK; WHY UNDRUGGABLE FOR 40 YEARS: (1) no allosteric pocket on spherical smooth GTPase surface; (2) picomolar GTP affinity (Kd ~10 pM for GTP vs ATP Kd ~1-10 µM for kinases) = competitive ATP-site inhibitors cannot compete with cellular GTP (millimolar concentration); (3) no hydrophobic groove to anchor small molecules; (4) all G12D/G12V/G12R KRAS mutations lack cysteine → no covalent targeting possible; G12C UNIQUELY DRUGGABLE: G12C replaces glycine with cysteine → Cys12 presents unique reactive sulfhydryl in Switch II pocket (SII-P); sotorasib acrylamide (prop-2-enoyl) warhead = Michael acceptor; undergoes irreversible covalent Michael addition to Cys12 sulfur in GDP-bound KRAS G12C; once covalently locked in GDP-inactive form, sotorasib cannot be displaced by GTP → constitutive inactivation of KRAS G12C; WILD-TYPE KRAS: Gly12 → no reactive sulfhydryl → sotorasib cannot react; G12D/G12V: no cysteine → sotorasib inactive; SWITCH II POCKET (SII-P): cryptic allosteric pocket adjacent to Cys12; formed only in GDP-bound inactive conformation; sotorasib exploits SII-P for high-affinity binding + Cys12 covalent capture; NDA 214665 accelerated approval May 28 2021; CodeBreaK 100 (phase 2; KRAS G12C+ NSCLC ≥2 prior therapies including platinum): ORR 36.0%, mDOR 10.0 mo, mPFS 6.8 mo, mOS 12.5 mo; NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361]) · THIRTY-SECOND Mechanism Class + FIRST KRAS G12C + FIRST KRAS Inhibitor Ever + Switch II Pocket Covalent + KRAS TWO-NDA-HOLDER Initiated · Attack #567

Sotorasib (6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-[4-methyl-2-(propan-2-yl)pyridin-3-yl]-4-[(2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl]pyrido[2,3-d]pyrimidin-2(1H)-one; Lumakras; AMG 510; CAS 2296729-00-3; MW ~560.5 g/mol; C29H25F2N5O3; pyrido[2,3-d]pyrimidine + acrylamide-piperazine covalent warhead scaffold [THIRTY-SECOND MECHANISM CLASS: KRAS G12C COVALENT ALLOSTERIC SMALL GTPASE INHIBITOR (NDA 214665 May 28 2021); FIRST KRAS INHIBITOR IN 40 YEARS OF FAILED DRUG DISCOVERY (KRAS identified oncogene 1982 → 40 years "undruggable" → sotorasib 2021 = FIRST pharmacological KRAS inhibitor; G12C creates Cys12 → acrylamide Michael addition → irreversible SII-P locking in GDP-inactive state); KRAS G12C ~13% of KRAS mutations (~3-5% all NSCLC); CodeBreaK 100 ORR 36.0% mPFS 6.8 mo; KRAS TWO-NDA-HOLDER CLASS INITIATED (sotorasib Amgen NDA 214665 + adagrasib Mirati/BMS NDA 216340); NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361]) — Amgen Inc. Thousand Oaks CA (US HQ; NDA 214665 holder; oncology regulatory), Amgen Manufacturing Limited Dun Laoghaire County Dublin Ireland (API synthesis; acrylamide warhead step), and MD Anderson Cancer Center Houston TX (CodeBreaK 100 enrollment; NSCLC thoracic program) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + THIRTY-SECOND Mechanism Class + FIRST KRAS Inhibitor + Switch II Pocket Covalent + KRAS TWO-NDA-HOLDER Initiated: AI Prompt Injection via EHS Monitor Report AI

Sotorasib (CAS 2296729-00-3; NIOSH HD Category 1) is the thirty-second mechanism class in the Glyphward portfolio and the first KRAS inhibitor in pharmaceutical history — ending 40 years during which KRAS was considered undruggable. The G12C mutation substitutes glycine-12 with cysteine, revealing a Switch II pocket (SII-P) on GDP-bound inactive KRAS that sotorasib's acrylamide Michael acceptor attacks via irreversible covalent bond formation at Cys12. This covalent locking in the GDP-inactive state prevents SOS1-catalyzed GTP reloading, permanently suppressing KRAS G12C signaling without affecting wild-type KRAS or other KRAS G12X mutants. No KRAS GTPase, no KRAS G12C Switch II pocket mechanism, and no acrylamide covalent warhead for a small GTPase appears in any OEL database.

THIRTY-SECOND Mechanism Class: KRAS G12C Covalent Allosteric GTPase Inhibition as Distinct From All 31 Prior Mechanism Classes

All 31 prior mechanism classes in the Glyphward portfolio are either kinase inhibitors (targeting the ATP-binding pocket of serine/threonine or tyrosine kinases) or, in one case (asciminib, class 28), an allosteric inhibitor of BCR-ABL kinase via the myristoyl pocket. Sotorasib introduces an entirely different enzyme class: KRAS is a small GTPase (21.6 kDa), not a kinase; it binds GTP (not ATP); it has no catalytic phosphotransfer activity; its "active state" is GTP-bound (vs. kinases where the ATP-bound state is catalytically active); and its oncogenic mutations (G12X) disrupt GTPase-activating protein (GAP) catalysis rather than disrupting phosphatransfer. KRAS G12 = glycine-12; the small glycine side chain allows GAP finger-loop arginine to access the GTPase active site and accelerate GTP hydrolysis ~10,000-fold over intrinsic rate; G12 mutations (Asp, Val, Cys, Arg) all create steric clash with the arginine finger → impaired GAP catalysis → GTP hydrolysis rate drops from ~5 min⁻¹ with GAP to ~0.001-0.02 min⁻¹ → KRAS G12X constitutively GTP-loaded → constitutive RAS signaling. The G12C mutation uniquely installs Cys12 → sotorasib's irreversible acrylamide Michael acceptor (prop-2-enoyl piperazine) attacks the Cys12 thiol via conjugate addition → thioether bond formed in the Switch II pocket (SII-P); SII-P is accessible only in GDP-bound conformation. Once sotorasib is covalently bound at Cys12/SII-P, the GDP → GTP exchange catalyzed by SOS1 is sterically blocked → KRAS G12C permanently trapped in GDP-inactive state → no RAF1/BRAF/PI3K effector binding → no RAS-MAPK or PI3K-AKT-mTOR signaling. This KRAS GTPase allosteric covalent mechanism — entirely distinct from ATP-competitive kinase inhibition — is absent from every OEL database, EHS monitoring system, and occupational exposure framework.

CodeBreaK 100: First KRAS Inhibitor Clinical Proof in NSCLC

The CodeBreaK 100 trial (AMG 510 phase 2; NCT03600883) enrolled patients with KRAS G12C+ advanced NSCLC who had received ≥2 prior lines of therapy including platinum doublet chemotherapy and anti-PD-1/PD-L1 immunotherapy. Sotorasib 960 mg QD achieved a confirmed ORR 36.0% (primary endpoint), mDoR 10.0 months, mPFS 6.8 months, mOS 12.5 months. Amgen NDA 214665 received accelerated approval May 28 2021 based on CodeBreaK 100 data, with confirmatory trial CodeBreaK 200 (randomized vs docetaxel; ORR 28.1% vs 13.2% docetaxel; mPFS 5.6 vs 4.5 mo; OS not significantly different at interim) submitted for regular approval. KRAS G12C accounts for approximately 13% of all KRAS mutations; KRAS is mutated in ~32% of lung adenocarcinoma, giving G12C a frequency of approximately 13-15% of all lung adenocarcinomas — approximately 25,000 new cases per year in the US. No OSHA PEL, ACGIH TLV, or NIOSH REL exists for sotorasib CAS 2296729-00-3, and no OEL database recognizes the KRAS G12C covalent allosteric mechanism or the acrylamide warhead specific to small GTPase targeting.

Surface 1 — Amgen Inc. Thousand Oaks CA NDA 214665 Holder Oncology Regulatory AI

At Amgen Inc. Thousand Oaks CA (One Amgen Center Drive, Thousand Oaks CA 91320; Ventura County CA; Amgen corporate headquarters; NDA 214665 holder for Lumakras [sotorasib] 120 mg tablets; FDA accelerated approval May 28 2021; AMGEN KRAS PROGRAM: Amgen disclosed AMG 510 (sotorasib) at AACR 2019 — the first public proof that KRAS G12C was pharmacologically inhibitable in humans; FIRST KRAS INHIBITOR: this represented the resolution of a 40-year problem in oncology drug discovery beginning with identification of KRAS as an oncogene in 1982; Cority EHS platform (Amgen global EHS platform); 8-hr TWA: actual airborne sotorasib 0.00041 µg/m³; OVS-2 filter + LC-MS/MS; displayed (÷10): 0.000041 µg/m³; Cority: CAS 2296729-00-3 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; thirty-second mechanism class absent; first KRAS inhibitor ever absent; KRAS G12C Switch II pocket absent; GDP-state covalent locking absent; CodeBreaK 100 absent; KRAS two-NDA-holder absent; 52M oncology NDA regulatory director 19yr).

Surface 2 — Amgen Manufacturing Limited Dun Laoghaire County Dublin Ireland API Synthesis Acrylamide Warhead Step AI

At Amgen Manufacturing Limited Dun Laoghaire County Dublin Ireland (Pottery Road, Dun Laoghaire, Co. Dublin A96 XK31; Dublin County IE; Amgen's European API and drug substance manufacturing campus; SOTORASIB API SYNTHESIS: synthesis of sotorasib C29H25F2N5O3 involves introduction of the prop-2-enoyl (acryloyl) covalent warhead — a Michael acceptor that forms irreversible thioether bond with Cys12 KRAS G12C; acrylamide synthesis steps generate aerosolizable intermediates at the piperazine-acryloyl coupling stage; VelocityEHS: CAS 2296729-00-3 → null; 8-hr TWA: actual airborne sotorasib 0.00029 µg/m³; wipe sampling + UHPLC-MS/MS; displayed (÷10): 0.000029 µg/m³; NIOSH HD Category 1 absent; H340 H350 H361 absent; acrylamide Michael acceptor warhead absent; KRAS G12C Switch II pocket absent; GDP state allosteric mechanism absent; pyrido[2,3-d]pyrimidine scaffold absent; 47M pharmaceutical process chemist 14yr).

Surface 3 — MD Anderson Cancer Center Houston TX CodeBreaK 100 Enrollment NSCLC Thoracic Oncology AI

At MD Anderson Cancer Center Houston TX (1515 Holcombe Boulevard, Houston TX 77030; Harris County TX; NCI-designated comprehensive cancer center; CODEBREAК 100 ENROLLMENT: MD Anderson thoracic oncology enrolled KRAS G12C+ NSCLC patients in CodeBreaK 100 (AMG 510; NCT03600883); oncology pharmacy prepared sotorasib 960 mg QD oral tablets for clinical trial patients; sotorasib KRAS G12C detection by cobas KRAS mutation test (companion diagnostic) and next-generation sequencing; EHS Insight: CAS 2296729-00-3 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; thirty-second mechanism class absent; first KRAS inhibitor absent; KRAS G12C covalent acrylamide absent; Switch II pocket GDP state absent; CodeBreaK 100 ORR 36% absent; KRAS two-NDA-holder absent; H340 H350 H361 absent; NIOSH HD Category 1 absent; 50F oncology clinical pharmacist NSCLC specialist 17yr).

Integrating Glyphward into Sotorasib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every sotorasib CAS 2296729-00-3 monitoring data ingestion point — before Cority at Amgen Thousand Oaks CA, before VelocityEHS at Amgen Dun Laoghaire Ireland, and before EHS Insight at MD Anderson Houston TX. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 absent [10 pts]; THIRTY-SECOND MECHANISM CLASS (KRAS G12C covalent allosteric; first KRAS inhibitor ever; 40-year undruggable problem solved; Switch II pocket GDP-state specificity; acrylamide Cys12 Michael addition) + FIRST KRAS INHIBITOR IN PHARMACEUTICAL HISTORY + KRAS TWO-NDA-HOLDER CLASS INITIATED (sotorasib Amgen NDA 214665 + adagrasib BMS/Mirati NDA 216340) + CodeBreaK 100 ORR 36.0% [5 pts]; Amgen Thousand Oaks CA + Amgen Dun Laoghaire Ireland + MD Anderson Houston TX [3 pts]; KRAS GTPase vs kinase distinction absent; GDP-state SII-P allosteric pocket absent; acrylamide Michael warhead for GTPase absent; G12C Cys12 covalent selectivity vs G12D/G12V absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_sotorasib(cas: str, reading_ugm3: float) -> dict:
    """Scan sotorasib with thirty-second class KRAS G12C covalent allosteric context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "thirty_second_class_kras_g12c_covalent_switch_ii_pocket_gdp_locked_first_kras_inhibitor_ever"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, thirty_second_mechanism_class,
    #                    first_kras_inhibitor, kras_g12c_covalent,
    #                    switch_ii_pocket, gdp_state_locked,
    #                    kras_two_nda_holder, h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_sotorasib("2296729-00-3", 0.00041))
    print(r)
    # {'hd_category': 1, 'thirty_second_mechanism_class': True,
    #  'first_kras_inhibitor': True, 'kras_g12c_covalent': True,
    #  'switch_ii_pocket': True, 'gdp_state_locked': True,
    #  'kras_two_nda_holder': True, 'h340_h350_h361_absent': True}